The AhR antagonist resveratrol (RSV) has been proven to exert a preservative effect on the IS/AhR/MAPK pathway to rescue IS-induced osteoblastogenesis exacerbation in chronic kidney disease patients [63]. This evidence concerns the gene AHR and chronic kidney disease.